Affiliation:
1. Université de Lorraine, CITHEFOR, F-54000 Nancy, France
2. Université de Lorraine, CNRS, L2CM, F-54000 Nancy, France
3. ABC Platform®, F-54505 Vandœuvre-lès-Nancy, France
Abstract
Amphotericin B is the oldest antifungal molecule which is still currently widely used in clinical practice, in particular for the treatment of invasive diseases, even though it is not devoid of side effects (particularly nephrotoxicity). Recently, its redox properties (i.e., both prooxidant and antioxidant) have been highlighted in the literature as mechanisms involved in both its activity and its toxicity. Interestingly, similar properties can be described for inorganic nanoparticles. In the first part of the present review, the redox properties of Amphotericin B and inorganic nanoparticles are discussed. Then, in the second part, inorganic nanoparticles as carriers of the drug are described. A special emphasis is given to their combined redox properties acting either as a prooxidant or as an antioxidant and their connection to the activity against pathogens (i.e., fungi, parasites, and yeasts) and to their toxicity. In a majority of the published studies, inorganic nanoparticles carrying Amphotericin B are described as having a synergistic activity directly related to the rupture of the redox homeostasis of the pathogen. Due to the unique properties of inorganic nanoparticles (e.g., magnetism, intrinsic anti-infectious properties, stimuli-triggered responses, etc.), these nanomaterials may represent a new generation of medicine that can synergistically enhance the antimicrobial properties of Amphotericin B.
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference124 articles.
1. From Nature to the Laboratory and into the Clinic;Nicolaou;Bioorg. Med. Chem.,2009
2. Synthesis and Biological Evaluation of Amphotericin B Derivatives;Volmer;Nat. Prod. Rep.,2010
3. Overview of Treatment Options for Invasive Fungal Infections;Pound;Med. Mycol.,2011
4. Sixty Years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections;Cavassin;Infect. Dis. Ther.,2021
5. Carolus, H., Pierson, S., Lagrou, K., and Van Dijck, P. (2020). Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance. J. Fungi, 6.